XML 21 R2.htm IDEA: XBRL DOCUMENT v3.25.4
Condensed Consolidated Balance Sheets - USD ($)
Dec. 31, 2025
Dec. 31, 2024
Current assets:    
Cash and cash equivalents $ 8,235,469 $ 8,999,496
Marketable securities 12,628,970 29,922,523
Prepaid expenses and other current assets 1,267,005 1,905,360
Deferred offering costs 320,581 0
Grant receivable 426,993 2,254,231
Total current assets 22,879,018 43,081,610
Total assets 22,879,018 43,081,610
Current liabilities:    
Accounts payable 1,454,118 1,511,440
Accrued expenses and other current liabilities 3,201,999 2,367,842
Total current liabilities 4,656,117 3,879,282
Total liabilities 4,656,117 3,879,282
Stockholders’ Equity:    
Common stock, $0.001 par value: 1,000,000,000 shares authorized at December 31, 2025 and 2024: 9,252,719 and 8,702,719 shares issued and outstanding at December 31, 2025 and 2024, respectively 9,252 8,702
Additional paid-in capital 115,905,684 109,868,913
Accumulated other comprehensive income 5,816 56,197
Accumulated deficit (97,697,851) (70,731,484)
Total stockholders' equity 18,222,901 39,202,328
Total liabilities and stockholders' equity 22,879,018 43,081,610
Series A Preferred Stock [Member]    
Stockholders’ Equity:    
Series A preferred stock $0.001 par value: 30,000,000 authorized at December 31, 2025 and 2024, 0 shares issued and outstanding at December 31, 2025 and 2024 $ 0 $ 0